Journal Article

Screening and Risk Analysis of Atrial Fibrillation After Radiotherapy for Breast Cancer: Protocol for the Cross-Sectional Cohort Study “Watch Your Heart (WATCH)”

Thariat, Juliette, Kirova, Youlia, Camilleri, Jeremy, Bernier, Marie-Odile, Broggio, David, Jimenez, Gaelle, Saint-Lary, Laura, Geffrelot, Julien, Jacob, Sophie, Panh, Loic, Levy, Christelle, Mandin, Corinne, Pinel, Baptiste, Boveda, Serge

2025

Overview

Atrial fibrillation (AF) after radiotherapy (RT) in patients with breast cancer (BC) is a relatively new and understudied topic. AF can increase the risk of stroke and other serious cardiovascular complications, compromising patients' quality of life and survival. Screening of AF, both asymptomatic and symptomatic forms, is therefore essential for optimal management. The aim of the Watch Your Heart After Radiotherapy for Breast Cancer (WATCH) study is to assess the incidence of AF (symptomatic or asymptomatic) occurring throughout a 5-year follow-up after RT and to investigate whether cardiac radiation exposure is associated with the occurrence of such events. WATCH is a cohort study that will include 200 patients over 65 years old, treated with RT for BC 5 years before inclusion and without a history of AF. Cross-sectional screening for AF at the time of the scheduled 5-year post-RT visit will be conducted by recording data from a Withings ScanWatch smartwatch for 1 month, confirmed by an electrocardiogram (ECG), and validated by a physician. In addition, a transthoracic echocardiography (TTE) will be performed, providing a comprehensive assessment of cardiac structures, and allowing us to investigate the underlying etiology and assess the risk of complications. Patients' medical records will provide retrospective information about the timing and risk factors for the occurrence of AF and other arrhythmias and cardiac diseases during the 5 years following RT. The development of deep learning algorithms for autosegmentation analysis of potentially critical substructures for the occurrence of AF, including cardiac chambers, the sinoatrial node, the atrioventricular node, coronary arteries, and pulmonary veins (PVs), will produce dosimetry linked to previous RT treatment for all contoured structures. Enrollment started in October 2023 and will continue until mid-2026 to include 200 patients, which will ensure an 80% statistical power to detect a significant difference in AF incidence around 15% for the group of patients moderately exposed (<75th percentile of the mean heart radiation dose) and 25% for the group of patients highly exposed (>75th percentile of the mean heart radiation dose). The results are expected by the end of 2026. This study will contribute to generating new knowledge on AF after RT for BC and help considering the inclusion of AF screening into routine clinical practice for these patients. Identifying the dose-risk associations would improve RT delivery protocols to limit the occurrence of different forms of AF and, if necessary, initiate appropriate treatment. ClinicalTrials.gov NCT06073509; clinicaltrials.gov/study/NCT06073509?id=NCT06073509&rank=1. DERR1-10.2196/67875.

• Publisher: JMIR Publications,JMIR publications
• Subject: Aged / Asymptomatic / Atrial Fibrillation - diagnosis / Atrial Fibrillation - epidemiology / Atrial Fibrillation - etiology / Breast cancer / Breast Neoplasms - radiotherapy / Cancer therapies / Cardiac arrhythmia / Cardiovascular disease / Chemotherapy / Cohort analysis / Cohort Studies / Cross-Sectional Studies / Dosimetry / Drug dosages / Echocardiography - methods / Electrocardiography / Female / Health risks / Heart / Humans / Incidence / Life Sciences / Lung cancer / Mass Screening - methods / Medical screening / Observational Studies as Topic / Protocol / Radiation therapy / Radiotherapy - adverse effects / Risk Assessment - methods / Risk Factors / Smartwatches / Thoracic surgery / Wearable computers / Womens health